PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
74.40%
Cash & equivalents yoy growth below half of TRVN's 912.74%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
74.40%
Below half of TRVN's 712.74%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.06%
Higher Other Current Assets Growth compared to TRVN's zero value, indicating worse performance.
70.82%
Below half of TRVN's 727.32%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.82%
Higher Total Assets Growth compared to TRVN's zero value, indicating better performance.
72.56%
Higher Accounts Payable Growth compared to TRVN's zero value, indicating worse performance.
-50.51%
Higher Short-Term Debt Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.03%
Higher Other Current Liabilities Growth compared to TRVN's zero value, indicating worse performance.
36.12%
Higher Total Current Liabilities Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.12%
Higher Total Liabilities Growth compared to TRVN's zero value, indicating worse performance.
10.25%
Higher Common Stock (Book Value) Growth compared to TRVN's zero value, indicating worse performance.
-4.93%
Both TRVN and the company show zero Retained Earnings Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
247.64%
Below half TRVN's 3776.96%. Michael Burry sees potential underperformance in building shareholder capital.
70.82%
Below half TRVN's 4067.46%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-50.51%
Higher Total Debt Growth compared to TRVN's zero value, indicating worse performance.
-77.35%
Less than half of TRVN's -912.74%. David Dodd sees better deleveraging or stronger cash buildup than competitor.